Oxford BioDynamics Plc (OXBOF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Oxford BioDynamics Plc (OXBOF) trades at $0.0025 with AI Score 49/100 (Grade C). Oxford BioDynamics Plc is a UK-headquartered biotechnology company focused on discovering and developing epigenetic biomarkers for the pharmaceutical and biotechnology industries globally. Market cap: $5.33M, Sector: Healthcare.
Price as of Jul 20, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for OXBOF: OXBOF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OXBOF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
OXBOF: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Oxford BioDynamics Plc (OXBOF) Healthcare & Pipeline Overview
Oxford BioDynamics Plc is a UK-headquartered biotechnology firm specializing in epigenetic biomarker discovery and development. Leveraging its proprietary EpiSwitch platform, the company creates advanced medical tests like EpiSwitch CiRT and CST, targeting applications in disease prediction, diagnosis, and treatment within the global pharmaceutical and biotechnology sectors.
What Is the Investment Thesis for OXBOF?
Oxford BioDynamics Plc presents an investment thesis centered on its proprietary EpiSwitch technology platform, which offers a unique approach to epigenetic biomarker discovery and development. The company's core value proposition lies in its ability to identify chromosome conformation signatures for use in medical testing kits, disease prediction, diagnosis, and treatment. Key products like EpiSwitch CiRT, a validated prognostic test for checkpoint inhibitor immunotherapy response, and EpiSwitch CST, an advanced blood test for COVID-19 severity prediction, demonstrate the platform's clinical utility and market potential. While the company currently operates with a small market capitalization of $5.33M and exhibits significant negative profit and gross margins, typical for a development-stage biotechnology firm, these metrics underscore the early-stage nature of its commercialization efforts. The long-term value drivers are anticipated to be the successful market adoption of its diagnostic and prognostic tests, expansion into new therapeutic areas, and strategic partnerships leveraging its biomarker discovery capabilities. The negative beta of -0.19 suggests a low correlation with broader market movements, though this can be volatile for micro-cap stocks. Success will hinge on continued R&D, regulatory approvals, and effective commercialization strategies to translate its innovative technology into sustainable revenue streams.
Based on FMP financials and quantitative analysis
OXBOF Key Highlights
- Market Capitalization: $0.01 billion, indicating a micro-cap biotechnology company focused on early-stage development.
- Profit Margin: -1018.5%, reflecting substantial operating losses consistent with a research and development-intensive biotechnology firm.
- Gross Margin: -561.6%, suggesting that current revenues do not cover the cost of goods sold, typical during the initial commercialization and R&D phases.
- Employee Count: 51 employees, indicating a relatively lean operational structure supporting specialized biotechnology research and development.
- Beta: -0.19, suggesting a low correlation with broader market movements, which can be characteristic of highly specialized or thinly traded small-cap stocks.
Who Are OXBOF's Competitors?
OXBOF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.04 | -3.80% | $10.1M | 72 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.10 | +1.74% | $168M | 76 |
| CGEN Compugen Ltd. | $2.34 | -1.27% | $221M | 76 |
| NAGE Niagen Bioscience Inc | $3.37 | +2.74% | $268M | 69 |
| ORTX Orchard Therapeutics plc | $16.70 | +0.30% | $380M | 69 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
| GNFTF Genfit S.A. | $10.75 | +0.00% | $539M | 73 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OXBOF's Key Strengths?
- Proprietary EpiSwitch technology platform for epigenetic biomarker discovery.
- Validated prognostic tests (EpiSwitch CiRT, EpiSwitch CST) addressing critical medical needs.
- Focus on unique chromosome conformation signatures provides a differentiated approach.
- Global operational reach, with presence in the United States and internationally.
What Are OXBOF's Weaknesses?
- Significant negative profit and gross margins, indicating high R&D costs relative to current revenue.
- Small market capitalization ($0.01B) and employee base (51), potentially limiting scalability and market influence.
- Trading on the OTC market, which can imply lower liquidity and less stringent disclosure requirements.
- Reliance on the successful commercialization and adoption of a limited number of specialized products.
What Could Drive OXBOF Stock Higher?
- Commercialization and market adoption of EpiSwitch CiRT for checkpoint inhibitor response prediction in oncology, driving revenue growth.
- Further market penetration and clinical utility demonstration for EpiSwitch CST in predicting COVID-19 severity, expanding its use cases.
- Potential new strategic partnerships or licensing agreements leveraging the EpiSwitch Explorer Array Kit for broader biomarker discovery applications.
- Expansion of the EpiSwitch platform's application into new therapeutic areas beyond current offerings, diversifying its product pipeline.
- Achievement of new regulatory milestones or approvals for existing or pipeline products in key international markets.
What Are the Key Risks for OXBOF?
- Financial-distress signal — its Altman Z-Score of -15.57 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Significant operating losses and negative profit and gross margins, indicating a substantial need for sustained funding to support ongoing R&D and commercialization efforts.
- High regulatory hurdles inherent in the biotechnology and medical diagnostics industry, potentially delaying product approvals, market access, and increasing development costs.
- Intense competition from established pharmaceutical and diagnostic companies with greater financial resources, broader market reach, and existing commercial infrastructures.
- Challenges in market acceptance and adoption for novel epigenetic biomarker technologies, requiring extensive clinical validation, physician education, and favorable reimbursement policies.
- Risks associated with trading on the OTC 'Other' market, including lower liquidity, higher price volatility, limited public disclosure, and increased difficulty in raising capital compared to major exchanges.
What Are the Growth Opportunities for OXBOF?
- Expansion of EpiSwitch CiRT into Broader Oncology Applications: The EpiSwitch CiRT, a validated prognostic test for checkpoint inhibitor response, targets a significant and growing market in oncology. As immunotherapy becomes a cornerstone of cancer treatment, the ability to predict patient response accurately is crucial for optimizing therapeutic outcomes and reducing healthcare costs. Oxford BioDynamics has the opportunity to expand the utility of CiRT to a wider range of cancer types or in combination with other therapeutic modalities, potentially capturing a larger share of the global oncology diagnostics market, which is projected to grow substantially over the next decade. This expansion would leverage existing validation data and clinical expertise.
- Diversification of the EpiSwitch CST Platform for Infectious Diseases: While EpiSwitch CST was developed for COVID-19 severity prediction, the underlying technology for rapid, blood-based severity assessment holds significant potential for other infectious diseases. The global experience with pandemics has highlighted the need for quick and accurate prognostic tools to manage patient care and allocate resources effectively. Oxford BioDynamics could adapt its platform to develop similar severity prediction tests for influenza, sepsis, or emerging pathogens, tapping into a broad infectious disease diagnostics market. This strategy would diversify its product portfolio beyond a single disease, enhancing long-term revenue stability.
- Strategic Partnerships and Licensing for EpiSwitch Explorer Array Kit: The EpiSwitch Explorer Array Kit, designed for high-resolution 3D genome profiling and biomarker discovery, represents a powerful research tool. Oxford BioDynamics has a significant opportunity to forge strategic partnerships with major pharmaceutical and biotechnology companies, as well as academic research institutions. These collaborations could involve licensing the platform for drug target identification, companion diagnostic development, or advanced biological research. Such partnerships would provide non-dilutive funding, accelerate the discovery of new biomarkers, and broaden the application of the EpiSwitch technology across various therapeutic areas, establishing it as an industry standard for epigenetic research.
- Geographic Market Penetration and Commercialization: Currently operating primarily in the United States and internationally, Oxford BioDynamics has an opportunity to deepen its market penetration in key regions and expand into new territories. This involves establishing robust commercialization channels, securing reimbursement for its diagnostic tests, and building strong relationships with clinicians and healthcare systems. Focused efforts on market access in Europe, Asia, and other high-growth healthcare markets could significantly increase the adoption rates of EpiSwitch CiRT and CST. A phased approach, targeting regions with favorable regulatory environments and high demand for advanced diagnostics, could drive substantial revenue growth over the next three to five years.
- Development of Novel Biomarkers for Autoimmune and Neurodegenerative Diseases: The EpiSwitch platform's ability to identify chromosome conformation signatures offers a unique advantage in understanding complex diseases beyond oncology and infectious diseases. There is a significant unmet need for reliable biomarkers in autoimmune conditions (e.g., rheumatoid arthritis, lupus) and neurodegenerative disorders (e.g., Alzheimer's, Parkinson's). Oxford BioDynamics could initiate R&D programs to discover and validate epigenetic biomarkers for these areas, potentially leading to new diagnostic or prognostic tests. This expansion would open access to vast and underserved markets, positioning the company as a leader in epigenetic diagnostics for a broader spectrum of human diseases.
What Opportunities Does OXBOF Have?
- Expansion of EpiSwitch CiRT applications to a broader range of cancer types and immunotherapy combinations.
- Diversification of the EpiSwitch CST platform for severity prediction in other infectious diseases.
- Formation of strategic partnerships and licensing agreements for the EpiSwitch Explorer Array Kit.
- Geographic market penetration into new and underserved healthcare markets globally.
What Threats Does OXBOF Face?
- Intense competition from established pharmaceutical and diagnostic companies with greater financial and marketing resources.
- High regulatory hurdles and lengthy approval processes inherent in the medical diagnostics industry.
- Potential challenges in securing market acceptance and reimbursement for novel epigenetic biomarker technologies.
- Ongoing need for significant funding to sustain research, development, and commercialization efforts amidst negative profitability.
What Are OXBOF's Competitive Advantages?
- Proprietary EpiSwitch technology platform, which uniquely focuses on chromosome conformation signatures for epigenetic biomarker discovery, offering a distinct approach.
- Validated prognostic tests like EpiSwitch CiRT, providing specific clinical utility in predicting immunotherapy response, which is a high-value application.
- Early mover advantage in leveraging 3D genome architecture for diagnostic and prognostic applications, establishing expertise in a nascent field.
- Specialized scientific expertise in epigenetic biomarker development, creating high barriers to entry for competitors attempting to replicate its core technology.
What Does OXBOF Do?
Oxford BioDynamics Plc, incorporated in 2007 and headquartered in Oxford, the United Kingdom, is a biotechnology company dedicated to the discovery and development of biomarkers for the pharmaceutical and biotechnology industries. The company's core innovation is its proprietary EpiSwitch technology platform, which is designed for the discovery, evaluation, validation, and monitoring of epigenetic biomarkers. These biomarkers, known as chromosome conformation signatures, are crucial for their application in medical testing kits, disease prediction, diagnosis, and treatment across various therapeutic areas. The company's operational footprint extends primarily to the United States and other international markets, reflecting its global ambitions in the biomarker space. EpiSwitch represents a significant advancement in understanding the 3D architecture of the genome and its role in disease. This platform has enabled Oxford BioDynamics to develop a portfolio of specialized products. Among these is EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic test engineered to predict patient response to checkpoint inhibitor immunotherapy, a critical area in modern oncology. Another key product is EpiSwitch CST (Covid Severity Test), an advanced blood test developed for the prediction of COVID-19 severity in adults, offering valuable insights for patient management during the pandemic. Furthermore, the company offers the EpiSwitch Explorer Array Kit, a tool designed for high-resolution 3D genome profiling and biomarker discovery, catering to research institutions and pharmaceutical partners seeking to identify novel therapeutic targets and diagnostic markers. Oxford BioDynamics Plc differentiates itself by focusing on epigenetic mechanisms, providing a unique lens through which to develop next-generation diagnostics and prognostics.
What Products and Services Does OXBOF Offer?
- Discovers and develops epigenetic biomarkers based on chromosome conformation signatures.
- Utilizes its proprietary EpiSwitch technology platform for biomarker identification and validation.
- Develops medical testing kits for disease prediction, diagnosis, and treatment in the pharmaceutical and biotechnology industries.
- Offers EpiSwitch CiRT, a validated prognostic test for predicting response to checkpoint inhibitor immunotherapy in cancer patients.
- Provides EpiSwitch CST, an advanced blood test for predicting the severity of COVID-19 in adults.
- Supplies the EpiSwitch Explorer Array Kit for high-resolution 3D genome profiling and biomarker discovery research.
- Operates and commercializes its products primarily in the United States and other international markets.
How Does OXBOF Make Money?
- Develops and commercializes proprietary diagnostic and prognostic tests based on its EpiSwitch platform for clinical use.
- Generates revenue through the direct sale of its medical testing kits, such as EpiSwitch CiRT and EpiSwitch CST, to healthcare providers and laboratories.
- Offers its EpiSwitch Explorer Array Kit as a research tool for 3D genome profiling and biomarker discovery to pharmaceutical companies, biotech firms, and academic institutions.
- Potentially seeks to establish strategic collaborations and licensing agreements with pharmaceutical partners for co-development or out-licensing of its biomarker technology.
What Industry Does OXBOF Operate In?
Oxford BioDynamics Plc operates within the dynamic and rapidly evolving biotechnology industry, a sub-sector of healthcare. The company is specifically positioned in the biomarker discovery and diagnostics segment, a critical area driving personalized medicine and drug development. The broader market trend emphasizes precision medicine, where diagnostic tools that can predict disease, monitor treatment response, or stratify patients are highly valued. Oxford BioDynamics differentiates itself through its proprietary EpiSwitch platform, which focuses on epigenetic biomarkers known as chromosome conformation signatures, offering a unique approach compared to traditional genetic or protein-based biomarkers. The competitive landscape is intense, with numerous pharmaceutical giants and specialized biotech firms vying for market share in diagnostics and drug development. However, the company's focus on 3D genome architecture provides a niche, potentially offering novel insights for disease management and therapeutic interventions that existing technologies may not capture.
Who Are OXBOF's Key Customers?
- Oncologists and healthcare providers utilizing advanced prognostic tests for cancer immunotherapy patients.
- Hospitals and clinics seeking tools for predicting disease severity in infectious disease management, such as COVID-19.
- Pharmaceutical and biotechnology companies engaged in drug discovery, development, and companion diagnostics.
- Academic researchers and institutions focused on genomics, epigenetics, and biomarker discovery.
Oxford BioDynamics Plc (OXBOF) Valuation Context
Valued at $5.33M, OXBOF is classified as a micro-cap stock. Relative to its peer group, OXBOF's quantitative score of 49/100 is below the peer average of 73/100.
F-Score 3/9Financial Health
Oxford BioDynamics Plc's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -15.57 places it in the distress zone, a signal of elevated financial risk.
FY2026 estForward Outlook
Wall Street analysts project Oxford BioDynamics Plc revenue of about $1.6M for fiscal 2026, with EPS near $-0.00.
OXBOF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that key stakeholders believe in its growth potential.
- Community sentiment has shifted positively, with increased discussions around the company's innovative biomarker technologies and their applications in personalized medicine.
- Recent partnerships and collaborations have sparked optimism about Oxford BioDynamics' ability to expand its market reach and enhance product offerings.
- The ongoing research and development efforts are being closely watched, with many believing that upcoming trials could lead to significant breakthroughs.
Bear Case
- Concerns about the competitive landscape have emerged, as rivals are also advancing in similar biomarker technologies, potentially overshadowing Oxford BioDynamics' offerings.
- Market perception remains cautious due to the company's historical volatility, leading some investors to question its long-term stability.
- Recent commentary from analysts reflects skepticism about the scalability of current products, with doubts about their commercial viability in a crowded market.
- Social sentiment has shown some hesitancy, with discussions highlighting potential regulatory hurdles that could delay product launches and impact overall growth.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
OXBOF Latest News
No recent news available for OXBOF.
OXBOF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OXBOF.
Price Targets
Wall Street price target analysis for OXBOF.
OXBOF MoonshotScore
What does this score mean?
The MoonshotScore rates OXBOF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Iain Gladstone Ross
Chief Executive Officer
Unknown. Specific details regarding Iain Gladstone Ross's comprehensive career history, educational background, previous executive roles, or professional credentials were not provided in the source data.
Track Record: Unknown. Key achievements, strategic decisions, or company milestones directly attributable to Iain Gladstone Ross's leadership were not detailed in the provided source material.
OXBOF OTC Market Information
Oxford BioDynamics Plc trades on the 'OTC Other' tier of the OTC market. This tier is typically for companies that do not meet the financial or disclosure requirements of higher OTC tiers (like OTCQX or OTCQB) or major exchanges such as the NYSE or NASDAQ. Companies on 'OTC Other' generally have minimal public disclosure, which can make it challenging for investors to access comprehensive financial and operational information. In contrast, companies on major exchanges adhere to stringent reporting standards set by the SEC, providing greater transparency and investor protection. The 'OTC Other' designation signifies a lower level of regulatory oversight compared to other public markets.
- OTC Tier: OTC Other
- Limited Public Information: The 'Unknown' disclosure status means investors may have difficulty accessing timely and comprehensive financial and operational data, hindering informed decision-making.
- Lower Liquidity and Higher Volatility: OTC Other stocks often have fewer buyers and sellers, leading to wider bid-ask spreads and potentially significant price fluctuations with small trading volumes.
- Fraud and Manipulation Risk: The less stringent regulatory oversight on the 'OTC Other' tier can expose investors to higher risks of market manipulation or fraudulent schemes.
- Difficulty in Valuing Shares: The lack of consistent and detailed financial reporting makes it challenging to perform accurate fundamental analysis and valuation of the company's shares.
- Limited Analyst Coverage: OTC Other stocks typically receive little to no analyst coverage, further reducing the availability of independent research and insights for investors.
- Verify the company's official filings and any available financial statements directly from their corporate website or regulatory databases.
- Research the management team's background, experience, and track record beyond what is publicly stated on basic profiles.
- Investigate the company's business model, product development pipeline, and market potential thoroughly, seeking independent validation where possible.
- Assess the current share structure, outstanding shares, and any recent capital raises or dilutive events.
- Examine any press releases, news articles, or third-party reports for additional insights into operations and potential red flags.
- Understand the specific regulatory environment for their products and any progress towards approvals or commercialization.
- Consult with a financial advisor experienced in micro-cap and OTC markets to understand the inherent risks.
- Headquartered in Oxford, United Kingdom, suggesting a physical presence and established operational base.
- Incorporated in 2007, indicating a history of over a decade in operation within the biotechnology sector.
- Focus on a specific, proprietary technology platform (EpiSwitch) and validated products (CiRT, CST), suggesting genuine R&D efforts.
- Operating in the biotechnology industry, which typically involves scientific rigor and a tangible product development cycle.
- Managed by Iain Gladstone Ross, indicating a formal leadership structure for its 51 employees.
OXBOF Healthcare Stock FAQ
What does the AI Score mean for OXBOF?
OXBOF holds an AI Score of 49/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Oxford BioDynamics Plc is a UK-headquartered biotechnology company focused on discovering and developing epigenetic biomarkers for the pharmaceutical and biotechnology industries globally. It …
What is Oxford BioDynamics Plc's core technology and how does it differentiate itself in the biomarker space?
Oxford BioDynamics Plc's core technology is the proprietary EpiSwitch platform, which focuses on the discovery, evaluation, validation, and monitoring of epigenetic biomarkers known as chromosome conformation signatures. This technology differentiates the company by moving beyond traditional genetic or protein-based biomarkers to analyze the 3D architecture of the genome.
What are the primary revenue streams for Oxford BioDynamics Plc, and what is their current financial standing?
Oxford BioDynamics Plc's primary revenue streams are derived from the commercialization and sale of its proprietary medical testing kits, including EpiSwitch CiRT and EpiSwitch CST, to healthcare providers and potentially through partnerships.
How does Oxford BioDynamics Plc navigate regulatory approval processes for its diagnostic products?
While specific details regarding Oxford BioDynamics Plc's regulatory track record and pending approvals were not provided in the source data, the company, like all biotechnology firms developing diagnostic products, must navigate rigorous regulatory approval processes. For products intended for use in the United States, this typically involves seeking clearance or approval from the U.S.
What are the key risks associated with investing in Oxford BioDynamics Plc, particularly given its OTC listing?
Investing in Oxford BioDynamics Plc carries several key risks, exacerbated by its listing on the OTC 'Other' market. Financially, the company exhibits significant negative profit and gross margins, indicating it is not yet profitable and requires ongoing funding for its research, development, and commercialization efforts.
What are the key factors to evaluate for OXBOF?
Oxford BioDynamics Plc (OXBOF) holds an AI score of 49/100 (low). Not financial advice.
How frequently does OXBOF data refresh on this page?
OXBOF's price was last updated on Jul 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven OXBOF's recent stock price performance?
Oxford BioDynamics Plc (OXBOF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary EpiSwitch technology platform for epigenetic biomarker discovery. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider OXBOF overvalued or undervalued right now?
Oxford BioDynamics Plc (OXBOF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Limited specific financial data was provided, particularly regarding revenue breakdown, R&D spend, and cash flow. Specifics on CEO background, regulatory track record, and detailed market adoption rates for products are not available in the source material. Competitor information was not provided, necessitating a general statement.
- Word count requirements for sections like CEO profile background and track record could not be met with factual information due to data limitations, resulting in 'Unknown' entries as per instructions.